{"meta":{"query_hash":"a3f01cd76920","filters":{"venue":"Experimental and Molecular Therapeutics"},"cohort_total":10,"direct_labels_cover":0,"predictions_cover":10,"exported":10,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a3f01cd76920","api":"https://metacan.xera.ac/api/v1/cohort?venue=Experimental+and+Molecular+Therapeutics"},"results":[{"id":"W2953614913","doi":"10.1158/1538-7445.sabcs18-2988","title":"Abstract 2988: Quantifying the Uptake of Metal Based Cancer Therapy Drugs Using Single Cell ICP-MS","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Analytical chemistry methods development","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"PerkinElmer Biosignal","funders":"","keywords":"Population; Cell; Cancer; Cancer cell; Drug; Computational biology; Cancer therapy; Drug discovery; Chemistry; Cancer research; Biology; Medicine; Bioinformatics; Pharmacology; Internal medicine; Biochemistry","score_opus":0.07683960953897799,"score_gpt":0.34104471455793817,"score_spread":0.26420510501896016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953614913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55726194,0.00552352,0.4006686,0.0010727146,0.0007688186,0.0006405841,0.008056688,0.005991738,0.020015463],"genre_scores_gemma":[0.6811639,0.005108353,0.28427994,0.0005515543,0.00013913456,0.0011215085,0.0063338596,0.0008492663,0.02045249],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991197,0.00007235137,0.000052412033,0.00028426322,0.00041772233,0.00005362047],"domain_scores_gemma":[0.99970406,0.00009342173,0.000030971507,0.000030447925,0.00012340763,0.000017606388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055510335,0.00057640707,0.0005155391,0.00076688227,0.00035655213,0.00073860167,0.000830021,0.001014613,0.0027934015],"category_scores_gemma":[0.00061906286,0.000285626,0.0002960841,0.0006074535,0.00049774576,0.00058683305,0.00040659402,0.000833911,0.0020502508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035089186,0.000018539544,0.00021559505,0.000106212596,0.000006659364,0.00002853381,0.00004089241,0.0001423327,0.9941507,0.0001536426,0.00058893097,0.0045127827],"study_design_scores_gemma":[0.000004436872,0.00005241309,0.0009407924,0.0000073071324,0.000009101248,0.00009255374,0.000032428343,0.0029454192,0.99064714,0.0001621405,0.0050970362,0.000009096918],"about_ca_topic_score_codex":0.00097035867,"about_ca_topic_score_gemma":0.0010918124,"teacher_disagreement_score":0.0027934015,"about_ca_system_score_codex":0.000695766,"about_ca_system_score_gemma":0.00039949192,"threshold_uncertainty_score":0.009344876},"labels":[],"label_agreement":null},{"id":"W2954084282","doi":"10.1158/1538-7445.sabcs18-2102","title":"Abstract 2102: Assessing glioma-protein inhibition in sunitinib-resistance using a 3-dimentional tissue-engineered renal cell carcinoma patient derived model","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Sunitinib; Renal cell carcinoma; Cancer research; Glioma; Medicine; Internal medicine","score_opus":0.022830930945331302,"score_gpt":0.28054517261782064,"score_spread":0.25771424167248935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954084282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295146,0.0016630323,0.008404109,0.00030431844,0.00015431142,0.0002034515,0.0019253781,0.00022632525,0.0041676103],"genre_scores_gemma":[0.97876143,0.0010521068,0.009892382,0.00020558677,0.000015454782,0.0002653489,0.0024926462,0.000040762374,0.007274202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997023,0.00003115298,0.000025683239,0.00005532137,0.0001393934,0.000046077406],"domain_scores_gemma":[0.99985397,0.000017409884,0.000038634207,0.000017697377,0.000025792764,0.000046580335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034260374,0.00038857863,0.00033000356,0.0003178274,0.00019538535,0.00034725474,0.00034324732,0.0006305709,0.0019488918],"category_scores_gemma":[0.000104616774,0.00016159602,0.00052670523,0.00022548277,0.00019030424,0.00022185702,0.0001835793,0.0008325335,0.000578902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003892004,0.00038135494,0.0004962442,0.00008828212,0.000020555719,0.00016219134,0.00003777719,0.00052933465,0.99487334,0.00023733712,0.00031635852,0.0024679957],"study_design_scores_gemma":[0.00006107133,0.0021440734,0.004407174,0.000008347791,0.00006246625,0.00071116205,0.000051159055,0.0040509105,0.9826246,0.000073110314,0.005790047,0.000015908208],"about_ca_topic_score_codex":0.0018247665,"about_ca_topic_score_gemma":0.0019121488,"teacher_disagreement_score":0.0019488918,"about_ca_system_score_codex":0.00047258113,"about_ca_system_score_gemma":0.00048098652,"threshold_uncertainty_score":0.0065196753},"labels":[],"label_agreement":null},{"id":"W2954925281","doi":"10.1158/1538-7445.sabcs18-2998","title":"Abstract 2998: Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Wnt signaling pathway; Medicine; Cancer stem cell; Breast cancer; Cancer; Paclitaxel; Medulloblastoma; Chemistry; Internal medicine; Signal transduction","score_opus":0.011270262596893278,"score_gpt":0.30375400375247347,"score_spread":0.2924837411555802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954925281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779382,0.0025148385,0.013948327,0.00024459584,0.000080678845,0.00011585535,0.00032808734,0.00024802535,0.004581506],"genre_scores_gemma":[0.9868618,0.0010522158,0.00656961,0.00008069176,0.000015528229,0.00008856722,0.00029062486,0.000045401845,0.004995523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990857,0.000011254377,0.000005125908,0.000020473426,0.000038479306,0.000016046466],"domain_scores_gemma":[0.99996793,0.0000051647085,0.000008624598,0.0000040026794,0.0000067715837,0.000007564016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083433,0.0002568374,0.00024119599,0.00016244542,0.000082822626,0.0001940214,0.00015868433,0.0002869003,0.0010546041],"category_scores_gemma":[0.00008167627,0.00009269518,0.00017398022,0.00010215636,0.00010577598,0.00016974757,0.00013824696,0.00035879546,0.0003183842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007167113,0.000044712706,0.00010627802,0.00003918283,0.000005528793,0.00004379109,0.000012425046,0.00017826214,0.9932862,0.00011011988,0.00017215686,0.0059297117],"study_design_scores_gemma":[0.000031479587,0.00051791844,0.00090517837,0.0000050667963,0.000017264038,0.00046029378,0.00000908394,0.0020081312,0.99092495,0.00003734833,0.005078029,0.0000053680014],"about_ca_topic_score_codex":0.0004697398,"about_ca_topic_score_gemma":0.0009595051,"teacher_disagreement_score":0.0010546041,"about_ca_system_score_codex":0.00024248843,"about_ca_system_score_gemma":0.00016369524,"threshold_uncertainty_score":0.0035280585},"labels":[],"label_agreement":null},{"id":"W4229834853","doi":"10.1158/1538-7445.sabcs18-3043","title":"Abstract 3043: Examination of NMT1 and NMT2 as independent prognostic markers and novel drug targets in adult acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Myeloid leukemia; Viability assay; Peripheral blood mononuclear cell; Biology; Context (archaeology); Flow cytometry; Myeloid; Cancer research; Leukemia; Apoptosis; Molecular biology; Immunology; In vitro; Biochemistry","score_opus":0.005465107945958638,"score_gpt":0.2371297582751926,"score_spread":0.23166465032923395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229834853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945029,0.002465098,0.00051315036,0.00015875307,0.000012212129,0.00001954575,0.001231324,0.000029768746,0.0010672534],"genre_scores_gemma":[0.99403316,0.0010364375,0.0010362145,0.000107269545,0.00003066985,0.000035155375,0.0027340993,0.000008691364,0.0009781652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998895,0.000020086933,0.000009274432,0.000023681532,0.000042758922,0.0000146779],"domain_scores_gemma":[0.9998623,0.000025293639,0.00004443467,0.000008222221,0.00003235735,0.000027377178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002713103,0.0001546387,0.00032125364,0.00040704195,0.0001327301,0.00031217234,0.00011996076,0.00019829326,0.0013132317],"category_scores_gemma":[0.00031890336,0.00006708866,0.00015098462,0.0005120009,0.000111990346,0.00013378359,0.0001256018,0.00023471337,0.00029371792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040507517,0.00016379211,0.13678268,0.0002692981,0.000112966496,0.0003933928,0.00005775765,0.0005484656,0.8157784,0.00019016313,0.0013747341,0.040277593],"study_design_scores_gemma":[0.00018953043,0.0018132101,0.74046075,0.000026736448,0.00022658698,0.0021100803,0.00007878592,0.00350678,0.24136554,0.00022916896,0.009977946,0.000014868817],"about_ca_topic_score_codex":0.0004937749,"about_ca_topic_score_gemma":0.0006128583,"teacher_disagreement_score":0.0013132317,"about_ca_system_score_codex":0.00029699728,"about_ca_system_score_gemma":0.00025483995,"threshold_uncertainty_score":0.00439322},"labels":[],"label_agreement":null},{"id":"W4234797906","doi":"10.1158/1538-7445.sabcs18-1282","title":"Abstract 1282: Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Tyrosine-kinase inhibitor; Breast cancer; Tyrosine kinase; Cancer; Medicine; Internal medicine; Receptor","score_opus":0.01660489894003939,"score_gpt":0.29726831005964294,"score_spread":0.2806634111196035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234797906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92804664,0.05773446,0.00402156,0.0018348187,0.00010327861,0.000063740525,0.00097037706,0.000065372114,0.007159801],"genre_scores_gemma":[0.97104734,0.021436682,0.0019333367,0.00033675428,0.00008664622,0.000034421177,0.0008206274,0.000008389678,0.004295766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999546,0.000005768334,0.0000029626367,0.000008679725,0.000015184628,0.000012883672],"domain_scores_gemma":[0.999969,0.0000043209216,0.000010963896,0.000001444896,0.000007438791,0.000006842911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001449591,0.00027461827,0.00027782161,0.00023592809,0.000113426744,0.0004369825,0.00020255234,0.00034274717,0.0019925912],"category_scores_gemma":[0.00008691231,0.000104478204,0.00021521437,0.0001774576,0.0001352319,0.00044755964,0.00015762824,0.0005350293,0.00041438444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065641536,0.00014434784,0.0029667176,0.0005962964,0.000026385802,0.00028774698,0.00005486094,0.0005552509,0.96880823,0.00041158948,0.00066699635,0.024825256],"study_design_scores_gemma":[0.00014482127,0.0025334393,0.20549576,0.00021676421,0.00020624204,0.0064080516,0.00040040663,0.009699225,0.7349399,0.0024072996,0.037505627,0.00004251347],"about_ca_topic_score_codex":0.0008700706,"about_ca_topic_score_gemma":0.001097562,"teacher_disagreement_score":0.0019925912,"about_ca_system_score_codex":0.00042916386,"about_ca_system_score_gemma":0.00023209413,"threshold_uncertainty_score":0.006665826},"labels":[],"label_agreement":null},{"id":"W4237965765","doi":"10.1158/1538-7445.sabcs18-3854","title":"Abstract 3854: Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Sting; Stimulator of interferon genes; Innate immune system; Immune system; Agonist; Biology; Medicine; Cancer research; Immunology; Cell biology; Receptor; Internal medicine","score_opus":0.02129384660175684,"score_gpt":0.27429051234084467,"score_spread":0.25299666573908786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237965765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986578,0.002102694,0.004660555,0.00020240096,0.00008025136,0.0005137444,0.0019981307,0.00017642214,0.0036878977],"genre_scores_gemma":[0.97712326,0.002896142,0.0047925906,0.00015593876,0.000025085526,0.00062000885,0.004291198,0.000040362178,0.0100556025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998797,0.000019062372,0.000010199947,0.00002143469,0.000031811745,0.000037707483],"domain_scores_gemma":[0.9999082,0.00001220549,0.000021254598,0.000010879014,0.000012550192,0.00003492924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002712989,0.0006846299,0.000410434,0.00035285836,0.00012833843,0.0002630943,0.00035706253,0.0005262468,0.0025123274],"category_scores_gemma":[0.00011550722,0.00016600301,0.00033462455,0.0002073589,0.00016697774,0.0003397969,0.000104024395,0.0009988996,0.00075213914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090495177,0.0012066927,0.00013786752,0.00009757288,0.000014422297,0.000059180777,0.000025164905,0.00048858736,0.9891824,0.00017387465,0.0003353056,0.0073740506],"study_design_scores_gemma":[0.00040454653,0.01750233,0.0017606879,0.000022587692,0.000059466616,0.00025108445,0.000019615656,0.0014156527,0.9728295,0.000062704166,0.005661321,0.000010486866],"about_ca_topic_score_codex":0.00058485137,"about_ca_topic_score_gemma":0.0009647493,"teacher_disagreement_score":0.0025123274,"about_ca_system_score_codex":0.00032513813,"about_ca_system_score_gemma":0.00036110243,"threshold_uncertainty_score":0.008404613},"labels":[],"label_agreement":null},{"id":"W4240718667","doi":"10.1158/1538-7445.sabcs18-2699","title":"Abstract 2699: Targeting an ubiquitin-activating enzyme in small-cell lung cancer (SCLC)","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Etoposide; Cancer research; Lung cancer; Cisplatin; Cancer; Cell culture; Medicine; Viability assay; Chemotherapy; Cancer cell; Cell; Biology; Oncology; Internal medicine; Genetics","score_opus":0.02517772543423411,"score_gpt":0.3542647523675444,"score_spread":0.32908702693331027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240718667","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98595643,0.006404739,0.0023481895,0.00027024877,0.00015511269,0.00018679211,0.0012693906,0.00019335038,0.0032156114],"genre_scores_gemma":[0.9872946,0.003700007,0.002958603,0.00012876058,0.000040015806,0.00012677159,0.0020385499,0.00002010029,0.0036925373],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998883,0.000014479487,0.0000114371005,0.000020154757,0.000037730573,0.00002787948],"domain_scores_gemma":[0.9999324,0.000011536375,0.000011209186,0.000005858919,0.00001227982,0.000026710935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017771192,0.00046882476,0.00036202828,0.0002925787,0.00021572366,0.00029476907,0.00028793694,0.00040206473,0.002540114],"category_scores_gemma":[0.000095011244,0.00011830483,0.00033031643,0.00030370505,0.00020352902,0.0001623559,0.00016699987,0.0007341551,0.0009474729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004990431,0.00024105376,0.00040100465,0.00022948728,0.00002125857,0.00017835555,0.000012642967,0.00023481158,0.9905337,0.00007443884,0.00042404066,0.007150236],"study_design_scores_gemma":[0.0001826735,0.005873649,0.004770065,0.000017126376,0.000097643424,0.0013719191,0.000038313457,0.0009689465,0.9806928,0.000069302914,0.005906054,0.000011380981],"about_ca_topic_score_codex":0.00056883396,"about_ca_topic_score_gemma":0.0012500004,"teacher_disagreement_score":0.002540114,"about_ca_system_score_codex":0.0002606428,"about_ca_system_score_gemma":0.00031307753,"threshold_uncertainty_score":0.008497536},"labels":[],"label_agreement":null},{"id":"W4241004874","doi":"10.1158/1538-7445.sabcs18-4805","title":"Abstract 4805: Cannabinoid WIN 55,212-2 induces endoplasmic reticulum stress in prostate cancer cells through CB<sub>1</sub>and CB2receptors","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"DU145; Cannabinoid receptor; AM251; Cannabinoid; Cannabinoid receptor type 2; Unfolded protein response; Cannabinoid Receptor Agonists; Endoplasmic reticulum; Receptor; Apoptosis; Chemistry; Cancer cell; Prostate cancer; Cancer research; Cell biology; Endocrinology; Internal medicine; Biology; Cancer; Medicine; Antagonist; LNCaP; Biochemistry","score_opus":0.006574682594756684,"score_gpt":0.24903899731229248,"score_spread":0.2424643147175358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241004874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784418,0.008269762,0.0019733168,0.00052975887,0.00027931298,0.00009831718,0.0018652447,0.0002615231,0.008280882],"genre_scores_gemma":[0.9704639,0.0044032778,0.0033453165,0.00041121047,0.00007362585,0.00011967591,0.0031626956,0.00002815524,0.017992223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986446,0.000014509606,0.00001216316,0.000017112041,0.000043838038,0.000047871043],"domain_scores_gemma":[0.9999683,0.0000035324813,0.0000060666716,0.0000036936613,0.000006342163,0.000012038675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086533306,0.00046298603,0.00041998088,0.00025588638,0.00024229128,0.00025321962,0.00022699856,0.00023082187,0.004046851],"category_scores_gemma":[0.00006337425,0.00010748724,0.00033507435,0.0003304623,0.00013907,0.00018826588,0.00016336654,0.00063735765,0.00080391084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010550818,0.0002382779,0.00034010698,0.00021536984,0.00002284275,0.00028258824,0.000023412078,0.000097215896,0.9911801,0.00022546835,0.00073670846,0.0055828635],"study_design_scores_gemma":[0.00015396647,0.0020541337,0.013168107,0.000019355131,0.00006425724,0.000883798,0.00006657564,0.0009021555,0.97360456,0.0000921856,0.008978872,0.0000119699025],"about_ca_topic_score_codex":0.002432169,"about_ca_topic_score_gemma":0.0030176856,"teacher_disagreement_score":0.004046851,"about_ca_system_score_codex":0.00038739468,"about_ca_system_score_gemma":0.00045964165,"threshold_uncertainty_score":0.013538063},"labels":[],"label_agreement":null},{"id":"W4248659508","doi":"10.1158/1538-7445.sabcs18-lb-269","title":"Abstract LB-269: Development of a vaccine model to track the CD8-specific response in Mauritius cynomolgus monkey","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"CTL*; Immune system; CD8; Cytotoxic T cell; Immunology; Immunotherapy; Cancer immunotherapy; T cell; Medicine; Biology; In vitro","score_opus":0.019769505183821222,"score_gpt":0.27037863218729646,"score_spread":0.25060912700347526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248659508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818771,0.001988285,0.0085664075,0.00048663342,0.00020274131,0.0008420867,0.0011369048,0.00026676033,0.0046330737],"genre_scores_gemma":[0.97381026,0.0011377336,0.010763604,0.00028358377,0.000066340035,0.001533453,0.0014080985,0.00005681592,0.010940225],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99975616,0.000031985404,0.0000165908,0.00007598746,0.000047842947,0.00007146093],"domain_scores_gemma":[0.9999007,0.000010097913,0.000023054343,0.000015282845,0.000011867722,0.000038927978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028944772,0.0005745296,0.00038333234,0.00070461514,0.00042268433,0.00028125857,0.00040107343,0.00060297933,0.0021439355],"category_scores_gemma":[0.00011291909,0.00014267191,0.00031684656,0.00019314354,0.00043628534,0.00028735856,0.00024040574,0.0008956216,0.0008475832],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006116005,0.0003925973,0.00036817757,0.00006352747,0.00000871055,0.00010239472,0.000049528448,0.00013106492,0.99468,0.00025415493,0.00021295594,0.0031252457],"study_design_scores_gemma":[0.00027575655,0.011164546,0.007731457,0.00005922833,0.00007546295,0.0012161322,0.00011421613,0.0028017147,0.95849454,0.00031732483,0.017725283,0.000024461202],"about_ca_topic_score_codex":0.0020604518,"about_ca_topic_score_gemma":0.001656421,"teacher_disagreement_score":0.0021439355,"about_ca_system_score_codex":0.0005952794,"about_ca_system_score_gemma":0.00046358907,"threshold_uncertainty_score":0.007172227},"labels":[],"label_agreement":null},{"id":"W4256129842","doi":"10.1158/1538-7445.sabcs18-3925","title":"Abstract 3925: A screen for epigenetic radiosensitizers in small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Experimental and Molecular Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Epigenetics; Cancer; Lung cancer; Computer science; Computational biology; Chemistry; Biology; Medicine; Oncology; Biochemistry; Genetics","score_opus":0.022115013067051548,"score_gpt":0.3432664170486949,"score_spread":0.3211514039816434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256129842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96584165,0.0128193395,0.005689174,0.00038970358,0.00011249395,0.0008645812,0.0047404747,0.0005390145,0.009003568],"genre_scores_gemma":[0.96077013,0.0071533,0.007718532,0.00027479685,0.00003800855,0.0002833512,0.008173233,0.000057394052,0.01553123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998611,0.00001402666,0.000011115659,0.00003272525,0.00005936433,0.000021667312],"domain_scores_gemma":[0.99994504,0.000009284638,0.000009752848,0.0000062400904,0.000010094876,0.000019527874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014418642,0.000630646,0.0005253414,0.0008218427,0.00023948973,0.00023207643,0.00041076634,0.00044289895,0.0043249447],"category_scores_gemma":[0.00012186125,0.0002221184,0.00048591412,0.0004512461,0.00014240171,0.00010730331,0.00025021206,0.0002790305,0.0009062596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018949197,0.00013728526,0.000577685,0.0001267425,0.000026283264,0.0002264736,0.0000154584,0.00022070494,0.9892005,0.000057958692,0.0003028064,0.008918622],"study_design_scores_gemma":[0.00014050552,0.0051898356,0.010359933,0.000042664557,0.00022152718,0.00092100055,0.000049556078,0.0007525426,0.9638919,0.00006165913,0.01835053,0.000018281153],"about_ca_topic_score_codex":0.00076113176,"about_ca_topic_score_gemma":0.002625963,"teacher_disagreement_score":0.0043249447,"about_ca_system_score_codex":0.00023138398,"about_ca_system_score_gemma":0.00030413852,"threshold_uncertainty_score":0.014468372},"labels":[],"label_agreement":null}]}